185 related articles for article (PubMed ID: 37062064)
1. Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain-only relapse versus synchronous extracranial relapse.
Xu F; Li J; Xing P; Liu Y; Wang Y
Cancer Med; 2023 Jun; 12(11):12495-12503. PubMed ID: 37062064
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
3. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
Jung HA; Lim J; Choi YL; Lee SH; Joung JG; Jeon YJ; Choi JW; Shin S; Cho JH; Kim HK; Choi YS; Zo JI; Shim YM; Park S; Sun JM; Ahn JS; Ahn MJ; Han J; Park WY; Kim J; Park K
Clin Cancer Res; 2022 Oct; 28(19):4312-4321. PubMed ID: 35838647
[TBL] [Abstract][Full Text] [Related]
5. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
[TBL] [Abstract][Full Text] [Related]
6. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
[TBL] [Abstract][Full Text] [Related]
7. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
[TBL] [Abstract][Full Text] [Related]
8. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
[No Abstract] [Full Text] [Related]
9. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
10. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases.
Lee HL; Chung TS; Ting LL; Tsai JT; Chen SW; Chiou JF; Leung HW; Liu HE
Radiat Oncol; 2012 Oct; 7():181. PubMed ID: 23110940
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
13. Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.
Sadoyama S; Sekine A; Satoh H; Iwasawa T; Kato T; Ikeda S; Sata M; Baba T; Tabata E; Minami Y; Nemoto K; Hayashihara K; Saito T; Okudela K; Ohashi K; Tajiri M; Ogura T
Clin Lung Cancer; 2018 Jan; 19(1):e29-e36. PubMed ID: 28669848
[TBL] [Abstract][Full Text] [Related]
14. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of postoperative recurrences in patients with clinical stage I NSCLC.
Chen YY; Huang TW; Tsai WC; Lin LF; Cheng JB; Chang H; Lee SC
World J Surg Oncol; 2014 Jan; 12():10. PubMed ID: 24410748
[TBL] [Abstract][Full Text] [Related]
16. Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort.
Machado-Rugolo J; Baldavira CM; Prieto TG; Olivieri EHR; Fabro AT; Rainho CA; Castelli EC; Ribolla PEM; Ab'Saber AM; Takagaki T; Nagai MA; Capelozzi VL
Braz J Med Biol Res; 2023; 56():e12488. PubMed ID: 37042869
[TBL] [Abstract][Full Text] [Related]
17. Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.
Li C; Shen Y; Hu F; Chu T; Yang X; Shao J; Zheng X; Xu J; Zhang H; Han B; Zhong H; Zhang X
Lung Cancer; 2020 Mar; 141():72-77. PubMed ID: 31955003
[TBL] [Abstract][Full Text] [Related]
18. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
He J; Su C; Liang W; Xu S; Wu L; Fu X; Zhang X; Ge D; Chen Q; Mao W; Xu L; Chen C; Hu B; Shao G; Hu J; Zhao J; Liu X; Liu Z; Wang Z; Xiao Z; Gong T; Lin W; Li X; Ye F; Liu Y; Ma H; Huang Y; Zhou J; Wang Z; Fu J; Ding L; Mao L; Zhou C
Lancet Respir Med; 2021 Sep; 9(9):1021-1029. PubMed ID: 34280355
[TBL] [Abstract][Full Text] [Related]
19. Impact of surgery and adjuvant chemotherapy on the survival of stage I lung adenocarcinoma patients with tumor spread through air spaces.
Lv Y; Li S; Liu Z; Ren Z; Zhao J; Tao G; Zheng Z; Han Y; Ye B
Lung Cancer; 2023 Mar; 177():51-58. PubMed ID: 36736075
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
Xu Y; Zheng M; Wang N; Wang R
Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]